Novavax Stock Buy Or | Sell

As of April 28, 2026, the consensus for Novavax (NVAX) is generally a , reflecting a stock in transition from a pandemic-focused entity to a leaner, partner-led biotech company. While strategic partnerships with Pfizer and Sanofi have strengthened the balance sheet, technical signals remain bearish in the short term. Investment Thesis Overview Novavax (NVAX): Buy, Sell, or Hold Post Q4 Earnings?